Viz.ai
AI-powered care coordination platform with 50+ FDA-cleared algorithms that alerts stroke teams within minutes of a CT scan.
Overview
Viz.ai is an enterprise AI care coordination platform founded in 2016 by neurosurgeon Dr. Chris Mansi and machine learning researcher Dr. David Golan. Its flagship product, Viz LVO, was the first AI software ever to receive FDA De Novo clearance for detecting large vessel occlusion (LVO) strokes on CT angiography and automatically notifying the treating team — a process that previously took an average of 52 minutes longer without the system. The platform has since expanded to 50+ FDA-cleared algorithms spanning neurovascular, cardiac, vascular, pulmonary, trauma, and oncology conditions, deployed across nearly 2,000 U.S. hospitals covering more than 230 million lives.
The Viz.ai One enterprise platform ingests DICOM images directly from hospital PACS systems, applies AI detection algorithms in real time, and pushes mobile alerts to the relevant specialists within a median of under 10 minutes from scan completion. Clinical studies report 90%+ click-through rates on its alerts and a 44% reduction in interfacility stroke transfer times. Beyond imaging triage, Viz.ai has built a life sciences arm providing real-world clinical intelligence to 13 pharmaceutical partners, and achieved profitability in its healthcare business in 2025. Revenue is estimated at around $65 million annually as of 2024-2025.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Viz.ai
- Sub-10-minute median CT-to-specialist-alert time for suspected LVO strokes
- Real-time mobile push notification to the neurovascular team with image thumbnails attached
- Automated ICH volume quantification report embedded in the clinical workflow
- Care coordination timeline dashboard for stroke network performance benchmarking
- FHIR/HL7-based EHR integration feeding AI findings directly into the patient chart
- Life sciences partner dashboard with de-identified, real-world patient-pathway insights
- Viz Assist workflow AI for clinical and administrative task automation within the hospital
ASEAN Perspective
Viz.ai in Southeast Asia
Viz.ai's clinical evidence base is drawn almost entirely from U.S. and European hospital networks, and no confirmed ASEAN or Asia-Pacific hospital deployments have been publicly announced as of mid-2026. Stroke burden in Southeast Asia is high — ASEAN countries account for a disproportionate share of global stroke mortality — making the platform's core use case directly relevant, but local regulatory clearances (HSA Singapore, BPOM Indonesia, Thai FDA, PMDA Japan) would need to be obtained before commercial deployment. Health systems in Singapore, Thailand, and Malaysia that wish to pilot AI stroke triage should also evaluate RapidAI and Aidoc, both of which have more documented APAC reference sites and may present lower localisation hurdles.
Viz.ai is a genuinely differentiated clinical AI platform with the strongest real-world deployment footprint in U.S. acute stroke care. Its De Novo FDA pathway (2018) set the regulatory benchmark for the category, and the platform's expansion to 50+ cleared algorithms across multiple disease states gives large health systems a single-vendor AI layer over their existing imaging stack. Clinical outcomes data — 44% reduction in transfer times, sub-10-minute median alert latency, and ~90% clinician click-through rates — are unusually robust for the sector and supported by peer-reviewed publications.
The platform's meaningful limitations are commercial and geographic: pricing is opaque enterprise-only, there is no self-service or SMB tier, and confirmed deployment is almost entirely in the United States with nascent EU presence and no documented ASEAN footprint. The API surface is a hospital-integration layer (FHIR/HL7/PACS) rather than a developer-accessible endpoint, which limits third-party extensibility. Competing platforms such as RapidAI have shown advantages in specific sub-conditions (medium vessel occlusions), and Aidoc's broader radiology triage scope positions it as a more horizontal alternative. For APAC health systems evaluating the platform, regulatory re-clearance in local markets (TGA, HSA, PMDA) and absence of regional reference sites are real procurement barriers.
What people say
Viz.ai is the category-defining AI care coordination platform for emergency stroke triage, backed by 50+ FDA clearances, deployment across nearly 2,000 U.S. hospitals, and peer-reviewed evidence of materially faster treatment times. Clinical adoption metrics are strong: ~90% alert click-through and a 44% reduction in interfacility transfer times. The platform achieved healthcare-segment profitability in 2025 and has expanded into cardiology, vascular, pulmonary, and oncology AI. The main caveats are an enterprise-only pricing model with no public rates, a limited APAC footprint, and a hospital-integration API rather than an open developer surface. Best suited for large U.S. and European health systems; ASEAN buyers face a regulatory localisation gap.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Viz.ai's 2018 FDA De Novo clearance was the first ever granted for an AI clinical decision support tool in emergency imaging triage.
- The platform assists in the care of one patient approximately every 32 seconds across its hospital network.
- Co-founder Dr. Chris Mansi was inspired to start the company after a patient died from delayed stroke treatment despite successful surgery.
- Viz.ai reached unicorn status ($1.2B valuation) in April 2022 led by Tiger Global and Insight Partners.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Viz.ai's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Viz.ai unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Viz.ai directly →
Spotted something out of date? Suggest an update →
More in Other
